The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer
Authors
Keywords
-
Journal
Oncogenesis
Volume 4, Issue 6, Pages e156-e156
Publisher
Springer Nature
Online
2015-06-08
DOI
10.1038/oncsis.2015.16
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SPHK1 regulates proliferation and survival responses in triple-negative breast cancer
- (2015) Arpita Datta et al. Oncotarget
- An improved syngeneic orthotopic murine model of human breast cancer progression
- (2014) Omar M. Rashid et al. BREAST CANCER RESEARCH AND TREATMENT
- Dietary Fat Intake and Development of Specific Breast Cancer Subtypes
- (2014) Sabina Sieri et al. JNCI-Journal of the National Cancer Institute
- Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory
- (2014) Nitai C Hait et al. NATURE NEUROSCIENCE
- S1PR1 Is Crucial for Accumulation of Regulatory T Cells in Tumors via STAT3
- (2014) Saul J. Priceman et al. Cell Reports
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720
- (2014) Shawn Baldacchino et al. EPMA Journal
- Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
- (2013) Berit Maria Müller et al. BMC CANCER
- Molecularly targeted therapies for metastatic triple-negative breast cancer
- (2013) Soley Bayraktar et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Protein phosphatase 2A: a target for anticancer therapy
- (2013) Danilo Perrotti et al. LANCET ONCOLOGY
- Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer
- (2013) Yuanyuan Li et al. Molecular Cancer
- Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond
- (2013) Gregory T. Kunkel et al. NATURE REVIEWS DRUG DISCOVERY
- Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1
- (2013) C Rutherford et al. Cell Death & Disease
- Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis
- (2012) Mariaelena Pierobon et al. BREAST CANCER RESEARCH AND TREATMENT
- S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites
- (2012) Jiehui Deng et al. CANCER CELL
- Sphingosine-1-Phosphate Links Persistent STAT3 Activation, Chronic Intestinal Inflammation, and Development of Colitis-Associated Cancer
- (2012) Jie Liang et al. CANCER CELL
- Sphingosine-1-Phosphate Produced by Sphingosine Kinase 1 Promotes Breast Cancer Progression by Stimulating Angiogenesis and Lymphangiogenesis
- (2012) M. Nagahashi et al. CANCER RESEARCH
- Molecular Targets of FTY720 (Fingolimod)
- (2012) M.R. Pitman et al. CURRENT MOLECULAR MEDICINE
- Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis
- (2012) Sahar A. Saddoughi et al. EMBO Molecular Medicine
- Targeting class I histone deacetylases in cancer therapy
- (2012) Geneviève P Delcuve et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Consumption of high-fat diet induces tumor progression and epithelial–mesenchymal transition of colorectal cancer in a mouse xenograft model
- (2012) Feng-Yao Tang et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Histone deacetylases and cancer
- (2012) Bruna Barneda-Zahonero et al. Molecular Oncology
- Role of Cholesterol in the Development and Progression of Breast Cancer
- (2011) Gemma Llaverias et al. AMERICAN JOURNAL OF PATHOLOGY
- Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model
- (2011) Yoanne Mousseau et al. BREAST CANCER RESEARCH AND TREATMENT
- Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells
- (2011) Yi Huang et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor-Positive Breast Cancer
- (2011) A. I. Phipps et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Functional Activation of the Estrogen Receptor- and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole
- (2011) G. J. Sabnis et al. CANCER RESEARCH
- FTY720 Analogues as Sphingosine Kinase 1 Inhibitors
- (2011) Keng G. Lim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- High Expression of Sphingosine 1-Phosphate Receptors, S1P1 and S1P3, Sphingosine Kinase 1, and Extracellular Signal-Regulated Kinase-1/2 Is Associated with Development of Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Patients
- (2010) Carol Watson et al. AMERICAN JOURNAL OF PATHOLOGY
- Dietary fat alters pulmonary metastasis of mammary cancers through cancer autonomous and non-autonomous changes in gene expression
- (2010) Michele La Merrill et al. CLINICAL & EXPERIMENTAL METASTASIS
- STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
- (2010) Heehyoung Lee et al. NATURE MEDICINE
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
- (2010) Volker Brinkmann et al. NATURE REVIEWS DRUG DISCOVERY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth
- (2009) Christina Restall et al. INTERNATIONAL JOURNAL OF CANCER
- Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate
- (2009) N. C. Hait et al. SCIENCE
- Developmental origins of disease and determinants of chromatin structure: maternal diet modifies the primate fetal epigenome
- (2008) Kjersti M Aagaard-Tillery et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More